Lanean...

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions

Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Fioramonti, Marco, Santini, Daniele, Iuliani, Michele, Ribelli, Giulia, Manca, Paolo, Papapietro, Nicola, Spiezia, Filippo, Vincenzi, Bruno, Denaro, Vincenzo, Russo, Antonio, Tonini, Giuseppe, Pantano, Francesco
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386748/
https://ncbi.nlm.nih.gov/pubmed/28223547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15390
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!